Physician profile
Nancy Perley
NPI 1295188282
$5,975.27
in general payments reported to CMS, 2019-2025
31 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $904 · 2022: $1,124 · 2023: $1,174 · 2024: $1,324 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,923 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.07 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $977.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $953.23 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $805.35 | 2022-2025 | |
| Novo Nordisk INC | $706.40 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Mannkind Corporation | $432.19 | 2021-2024 | Afrezza |
| Abbott Laboratories | $283.95 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $248.73 | 2024-2025 | Tepezza, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $234.40 | 2021-2025 | |
| Corcept Therapeutics | $149.75 | 2023-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $116.04 | 2021-2022 | |
| Insulet Corporation | $114.50 | 2021-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $108.32 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Becton, Dickinson and Company | $98.70 | 2021-2022 | |
| Bigfoot Biomedical INC | $89.97 | 2022 | |
| Horizon Therapeutics Plc | $86.99 | 2022-2023 | Tepezza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $78.22 | 2023-2025 | Cequr Simplicity |
| Vistapharm, INC. | $57.04 | 2021 | |
| Beta Bionics, INC. | $46.46 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $41.79 | 2021 | |
| Tolmar, INC. | $39.62 | 2024-2025 | Jatenzo |
| Medtronic, INC. | $38.94 | 2024 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $35.84 | 2024-2025 | |
| Ionis Pharmaceuticals, INC. | $33.36 | 2025 | Tryngolza |
| Radius Health, INC. | $30.61 | 2025 | Tymlos |
| Alvogen INC | $30.58 | 2023 | Teriparatide |
| Neurocrine Biosciences, INC. | $28.30 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.17 | 2024 | Jardiance |
| Abbvie INC. | $25.67 | 2021 | |
| Tandem Diabetes Care, INC. | $21.26 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Shield Therapeutics INC | $19.83 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Perley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.